Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Summary
PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing. The financing was led by Korea Investment Partners (KIP) – Global Bio Fund with strong participation from all existing Series A investors including, notably, Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The proceeds will be used for the expansion of the companys GT-30 Phase Ib/IIa clinical trial evaluating its personalized neoantigen-targeting vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. "The Series A1 financing demonstrates our investors confidence in the GT-EPIC platform to design and manufacture patient-specific personalized cancer vaccines," said Dr. Niranjan Y. Sardesai, Founder and Chief Executive Officer of Geneos Therapeutics. The platform is developed to deliver the following key advantages: ability to drive potent and broad T cell immune responses, capability to target an unprecedented number of neoantigens in a single formulation, and a rapid manufacturing turnaround time.